Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Saved in:
| Title: | Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. |
|---|---|
| Authors: | Dosne AG; Janssen Research and Development, Beerse, Belgium., Valade E; Janssen Research and Development, Beerse, Belgium., Goeyvaerts N; Janssen Research and Development, Beerse, Belgium., De Porre P; Janssen Research and Development, Beerse, Belgium., Avadhani A; Janssen Research and Development, Spring House, PA, USA., O'Hagan A; Janssen Research and Development, Spring House, PA, USA., Li LY; Janssen Research and Development, Spring House, PA, USA., Ouellet D; Janssen Research and Development, Spring House, PA, USA., Perez Ruixo JJ; Janssen Research and Development, Beerse, Belgium. jjperezr@ITS.JNJ.com. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Feb; Vol. 89 (2), pp. 151-164. Date of Electronic Publication: 2022 Jan 03. |
| Publication Type: | Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-021-04381-4 |
